Symposium Addresses Unique Needs of Young Adults with Rheumatic Diseases PDF Print E-mail
Wednesday, 05 October 2011 07:55

The Arthritis Foundation is sponsoring the 2nd Annual Arthritis in PrimeTime symposium on Saturday, October 22 at the Long Beach Renaissance Hotel in Long Beach. This premier educational and motivational event fosters active and fulfilling lives for young adults (ages 17-45 years old) affected by arthritis, fibromyalgia, lupus, scleroderma, ankylosing spondylitis and other chronic diseases. 



The event's theme is "Making My Work Work–"Work" being broadly defined as college, disability, life transitions, home-making or career. Led by top medical experts and advocates, informational sessions will educate hundreds of participants with chronic diseases about diverse lifestyle issues (including transition from college to the job market, workplace success, social relationships and health insurance issues), as well as research updates and medical treatments for pain management.  

"Most people do not know that arthritis is the #1 cause of work disability in the United States," said Arthritis in PrimeTime chair, Amye Leong, M.B.A. "Arthritis in PrimeTime is a positive, motivating event designed to help over 11 million young people affected with arthritis and other rheumatic diseases lead active, productive lives."  Ms. Leong, who was wheelchair-bound by rheumatoid arthritis, is today the international spokesperson for the United Nations Bone and Joint Decade.

Arthritis in PrimeTime is made possible through the Jane Wyman Trust and Pfizer, and is conducted in partnership with LupusLA, National Fibromyalgia Association, Scleroderma Foundation, Spondylitis Association of America, and Arthritis Introspective. 

The symposium begins at 9 a.m., and ends with an inspirational closing address by Matt Iseman, M.D., renowned comedian and host of Style Network's "Clean House."  Tickets are $25 each or $40 per couple. 

For more information or to register for this event, visit www.arthritisinprimetime.org or contact Jennifer Ziegler at the Arthritis Foundation at 323.954.5760 Ext. 243.

Source: PRNewswire


 
More articles :

» Scleroderma Drug In Development

According to , has partnered with , the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.The money will...

» Simple Predictor In Scleroderma Related Interstitial Lung Disease

Patients at high risk of deterioration or death from Systemic Sclerosis-related interstitial lung disease can be readily spotted using CT scans, suggest Melbourne researchers.Patients classified as having “extensive” (> 20%) lung disease as...

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...

» Autoimmune Disease Overlap Syndromes

Because of their variable features, overlapping autoimmune connective tissue, thyroid and liver disorders can be difficult to diagnose.It’s not unusual for several years to go by before overlapping autoimmune conditions are properly diagnosed. One...

» arGentis Issued Key Patent Related to Treating Fibrosing Diseases by Induction of Immune Tolerance

arGentis Pharmaceuticals, LLC today announced the issuance of United States patent 7,718,765, entitled “Methods for Treating Fibrosing Diseases by Induction of Immune Tolerance." The issued patent, based on the seminal research of Arnold E....

» Potential Therapy for Scleroderma Lung Disease Uncovered

Investigators, partially supported by the , have found that a deficiency in the protein caveolin-1 (cav-1) is linked to the development of, the scarring of lung tissue that causes disability and death in people with . The scientists, from the...